Identification of individuals at increased genetic risk for a complex disorder such as coronary disease can facilitate treatments or enhanced screening strategies. A rare monogenic mutation associated with increased cholesterol is present in ~1:250 carriers and confers an up to 4-fold increase in coronary risk when compared with non-carriers. Although individual common polymorphisms have modest predictive capacity, their cumulative impact can be aggregated into a polygenic score. Here, we develop a new, genome-wide polygenic score that aggregates information from 6.6 million common polymorphisms and show that this score can similarly identify individuals with a 4-fold increased risk for coronary disease. In >400,000 participants from UK Biobank, the score conforms to a normal distribution and those in the top 2.5% of the distribution are at 4-fold increased risk compared to the remaining 97.5%. Similar patterns are observed with genome-wide polygenic scores for two additional diseases -breast cancer and severe obesity.
Main Text:
The identification of individuals at increased genetic risk for a common, complex disease can facilitate treatment or enhanced screening strategies to prevent disease manifestation. For example, with respect to coronary disease, ~1:250 individuals carry a rare, large-effect genetic mutation causal for increased low-density lipoprotein cholesterol (1) (2) (3) . A recent analysis in a large U.S. health care system demonstrated that such individuals have an odds ratio for coronary disease of 2.6 when compared to non-carriers and an odds ratio of 3.7 for early-onset disease (1) . Aggressive treatment to reduce circulating low-density lipoprotein cholesterol levels among carriers of such mutations can reduce coronary disease risk (4) .
Beyond rare monogenic mutations, a decade of genome-wide association studies (GWAS) has demonstrated that common single nucleotide polymorphisms contribute to a range of complex diseases (5) . However, because the effect size of such polymorphisms tends to be modest, any individual polymorphism has limited utility for risk prediction. Polygenic scores (PS) provide a mechanism for aggregating the cumulative impact of common polymorphisms by summing the number of risk variant alleles in each individual weighted by the impact of each allele on risk of disease (6) . We recently demonstrated that a coronary disease PS consisting of 50 common variants that had achieved genome-wide levels of statistical significance in previous studies can stratify the population into varying trajectories of risk (7, 8) .
Simulated analyses based on GWAS effect size distributions suggest that the predictive power of such PSs may be markedly improved by considering a genome-wide set of common polymorphisms (9) (10) (11) . But, it remains uncertain whether the extreme of a PS distribution can confer risk equivalent to a monogenic mutation (e.g., 4-fold increased risk). Here, we demonstrate that a PS comprised of a genome-wide set of common variants permits identification of individuals with 4-fold increased risk for coronary disease and subsequently generalize this approach to two additional complex diseases, breast cancer and severe obesity.
In order to develop an optimized polygenic score for coronary disease, we derived two new PSs and compared them with two previously published scores in a testing dataset of 120,286 individuals of European ancestry from the UK Biobank -4,831 with coronary disease and 115,455 controls (7, 12, 13) . The UK Biobank is a large observational study that enrolled individuals aged 45 to 69 years of age from across the United Kingdom beginning in 2006 (14) .
We derived the two new PSs using summary association statistics from our earlier GWAS as a starting point for the relationship of millions of common polymorphisms to risk for coronary disease (Supp. Methods ; 15) . A reference population of 503 Europeans from the 1000 Genomes study was used to assess the correlation of a given polymorphism with others nearby ('linkage disequlibrium') (16) . For the first score, we implemented a 'pruning and thresholding' strategy (PS P&T ) to combine independent variants (r 2 < 0.8 with other nearby variants) that exceeded nominal significance (p-value < 0.05) in the previous GWAS. For the second score, we used the recently developed LDPred computational algorithm (17) . This involves a Bayesian approach to calculate a posterior mean effect for all variants based on a prior (effect size in the prior GWAS) and subsequent shrinkage based on linkage disequilibrium.
All four scores demonstrated robust association with coronary disease in the testing dataset. But, the newly-derived genome-wide polygenic score of 6.6 million common single nucleotide polymorphisms (PS GW ) demonstrated the maximal area-under-the-curve of 0.64 and was selected for use in subsequent analyses ( Table 1) .
Next, we sought to validate this score in an independent dataset of the remaining 288,890 individuals of European ancestry in the UK Biobank. Mean age was 57 years and 55% of the cohort was female. 8676 (3.0%) of the participants had been diagnosed with coronary disease, as defined based on verbal interview with a trained nurse or hospitalization for myocardial infarction or coronary revascularization in the electronic health record prior to enrollment.
We tested the hypothesis that individuals with high PS GW might have risk equivalent to a monogenic coronary disease mutation (e.g., four-fold increased risk) by assessing progressively more extreme tails of the PS GW distribution and comparing risk with the remainder of the population (Table 2; Fig. 1A ). Across UK Biobank participants, PS GW conformed to a normal distribution and individuals in the top 2.5% of the PS GW distribution had a four-fold increased coronary disease risk (odds ratio 3.96) when compared with the remaining 97.5% of the population in a logistic regression model adjusted for age, sex, genotyping array, and the first four principal components of ancestry. We defined those individuals in the top 2.5% of the distribution as having high PS GW in subsequent analyses.
Coronary disease was noted in 663 of 7225 (9.2%) individuals with high PS GW as compared to 8013 of 281,755 (2.8%) of those in the remainder of the distribution (Fig. 1B) . Of the 8676 individuals with coronary disease, 663 (7.6%) were predisposed on the basis of high PS GW . Several traditional coronary disease risk factors including family history of heart disease were enriched in those with high PS GW ( Table 3) . However, attenuation in the risk estimate for high PS GW was modest after additional adjustment for history of hypertension, type 2 diabetes, hypercholesterolemia, current smoking, and family history of heart disease (adjusted odds ratio 3.15; 95% confidence interval 2.86 -3.46).
In order to assess the generalizability of these observations, we used a similar approach to construct separate PSs for two additional complex diseases with major public health implications -breast cancer and severe obesity. As for coronary disease, we used summary association statistics from large prior GWASs as a starting point for the relationship of common polymorphisms to breast cancer or body-mass index (18, 19) .
Among 157,897 females of the UK Biobank validation dataset, 6567 (4.2%) had been diagnosed with breast cancer at the time of enrollment. Individuals with high PS for breast cancer had a 2.9-fold increased risk when compared with the remaining 97.5% of the population ( Table 4) . Breast cancer was noted in 10.5% of individuals with high PS as compared to 4.0% of those in the remainder of the distribution (Fig S1) . Of individuals with breast cancer, 6.4% were predisposed on the basis of high PS. Attenuation in the risk estimate for high PS was modest after additional adjustment for family history of breast cancer, age at menarche, current smoking, body-mass index, and previous use of hormonal replacement therapy (adjusted odds ratio 2.78 95% confidence interval 2.49 -3.09; Table S1) Among 288,018 individuals of the UK Biobank validation dataset with body-mass index available, 5232 (1.8%) were severely obese at the time of enrollment, defined as body-mass index ≥ 40 kg/m 2 . Individuals with high PS had a 5.5-fold increased risk of severe obesity when compared with the remaining 97.5% of the population ( Table 4) . Severe obesity was noted in 8.4% of individuals with high body-mass index PS as compared to 1.6% of those in the remainder of the distribution (Fig S2) . Of individuals with severe obesity, 11.6% were predisposed on the basis of high PS. Results were similar when considering a less stringent definition for obesity of body-mass index ≥ 30 kg/m 2 (Table S2) .
For three common diseases, we demonstrate that the incorporation of a genome-wide set of common polymorphisms into a PS can identify subsets of the population at substantially increased risk.
These results permit several conclusions. First, we provide empiric evidence that the cumulative impact of common polymorphisms on risk of disease can approach that of rare, monogenic mutations. The predictive capacity of PSs will likely continue to improve as larger discovery GWAS studies more precisely define the effect sizes for common polymorphisms across the genome (9-11). Second, high PS GW seems operable in a much larger fraction of the population as compared to rare monogenic mutations. For coronary disease, the largest gene-sequencing study to date identified a monogenic driver mutation related to increased low-density lipoprotein cholesterol in 94 of 12,298 (0.76%) afflicted individuals (1). Here, we identify high PS GW in 7.6% of individuals with coronary disease, a prevalence an order of magnitude higher. Third, traditional risk factor differences of high PS GW individuals versus the remainder of the distribution are modest and these individuals would thus be difficult to identify without direct genotyping. Fourth, a key advantage of a DNA-based diagnostic such as PS GW is that it can be assessed from the time of birth, well before the discriminative capacity of most traditional risk factors emerges, and may thus facilitate intensive prevention efforts. For example, we recently demonstrated that high polygenic risk for coronary disease may be offset by adherence to a healthy lifestyle or cholesterol-lowering therapy with statin medications (8, 20, 21) . Finally, we demonstrate similar patterns for two additional heritable diseases -breast cancer and severe obesity -suggesting that this approach will provide a generalizable framework for risk stratification across a range of common, complex diseases.
Several limitations deserve mention. First, the risk associated with a high polygenic score is not the result of a discrete underlying mechanism, but rather a quantitative blend of numerous risk pathways. Monogenic mutations predispose to disease on the basis of a specific driving pathophysiology that can sometimes enable targeted therapy. For example, homozygous deficiency in the POMC gene is associated with extreme obesity and precise targeting of the perturbed pathway can lead to significant weight loss (22) . However, this monogenic etiology of obesity is exceedingly rare in the general population (23) . To the extent that strategies to mitigate increased risk have utility regardless of underlying mechanism (e.g., statin therapy for coronary disease, dietary modification for severe obesity, or mammography screening for breast cancer), identification of individuals with high polygenic risk may prove useful. Second, the polygenic scores described here were derived and tested in individuals of European ancestry. Because allele frequencies, linkage disequilibrium patterns, and effect sizes of common polymorphisms vary by ancestry, future studies are needed to extend this approach across additional ancestral backgrounds (24) . Lastly, the potential utility of genetic risk disclosure must be weighed against possible untoward consequences, including increased cost of care, psychological distress or discrimination, and a sense of fatalism in those at high risk. Additional work is needed to optimize genetic risk disclosure to patients and their health care providers and to test whether such disclosure can improve clinical outcomes. Supplementary Materials:
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